Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this case study, a 64-year-old female with breast cancer undergoing ADC therapy experienced significant hair regrowth using oral minoxidil, suggesting its potential as a treatment for ADC-induced alopecia.

This source reports that trastuzumab deruxtecan improves outcomes in HER2-positive and HER2-low metastatic breast cancer, emphasizing the need for careful adverse event monitoring, particularly for interstitial lung disease, and managing emetic risk to maximize benefits.

This meta-analysis reports that trastuzumab deruxtecan is effective and has an acceptable safety profile for treating HER2-low or positive advanced breast cancer, although further research is recommended to support individualized treatment strategies.

This review discusses managing common and notable adverse events associated with the antibody-drug conjugate trastuzumab deruxtecan in patients with HER2-positive unresectable/metastatic breast cancer and reports no new clinical results.

This article reviews strategies for managing the side effects of cytotoxic chemotherapy in primary healthcare settings and reports no new clinical findings.